Immunovant Financial Ratios
NASDAQ: IMVTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
30.47+0.21 (+0.69%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Immunovant ratio analysis
Return on equity reached -59.3%, meaning Immunovant generated -0.59 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Immunovant financial ratios (annual)
| Ratio | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Price / book | 5.24 | 3.12 | 7.22 | 5.27 | 1.30 | 3.78 | 6.52 | — |
| Return on equity (ROE) | -59.3% | -58.5% | -42.0% | -58.2% | -33.4% | -27.4% | -70.6% | -389.7% |
| Return on assets (ROA) | -52.8% | -53.3% | -38.9% | -52.0% | -30.4% | -26.0% | -60.7% | -206.8% |
| Current ratio | 9.09 | 11.16 | 13.70 | 9.34 | 11.52 | 21.79 | 7.12 | 41.87 |